Navigation Links
Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
Date:4/29/2008

ing time to tumor progression, duration of response, overall patient survival and safety parameters. Patients may continue to receive bavituximab alone after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable.

Tumor response in this study will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) parameters. The trial is being conducted in the Republic of Georgia according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) standards.

The National Cancer Institute estimates that approximately 178,480 U.S. women were diagnosed with cancer of the breast in 2007 and about 40,460 women died of the disease. According to the World Health Organization, breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths.

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is usually located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase Ib pilot trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. Peregrine has received regulatory approval to conduct three Phase II trials to study the anti-tumor effects of bavituximab in combination with chemotherapy. These include two breast cancer protocols and a non-small cell lung cancer protocol. Bavituximab is in clinical trials in the U.S. in patients with advanced solid tumors and in patients co-infected with HCV and HIV.

'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
2. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
3. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
4. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
5. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
6. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ... biology, human genetics, genomic technology, and drug discovery ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014 /PRNewswire/ ... "Lifetime in Dermatology Achievement Award" from the Journal ... Orlando Dermatology Aesthetic & Clinical Conference (ODAC). The event ... in Florida . ... comprehensive report on the practice of dermatology for clinical ...
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of ... able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Device Industry, it steadfastly remains one of ... involving IP infringement. This litigious nature can ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
... Bedford Laboratories™, a division of Ben Venue Laboratories, ... Topotecan Hydrochloride for Injection, 4 mg (base)/vial to ... the reference listed drug Hycamtin ® (topotecan ... Injection is indicated for the treatment of metastic ...
... Nektar Therapeutics (Nasdaq: NKTR ) will announce ... 2011 on Wednesday, April 27, 2011, after the close of ... will host a conference call to review the results beginning ... The press release and a live audio-only ...
Cached Medicine Technology:Bedford Laboratories™ to Begin Shipping Topotecan Hydrochloride for Injection, 4mg SD Vial 2Nektar to Announce Financial Results for the First Quarter of 2011 on Wednesday, April 27, 2011, After Close of U.S.-Based Financial Markets 2
(Date:4/15/2014)... States have nearly doubled since 1988, suggests new research ... with obesity apparently to blame for the surge. The ... has not hit all groups equally, with alarming increases ... According to new research reported in the April 15, ... , diabetes increased from 6 percent to 10 percent ...
(Date:4/15/2014)... have solved a decades-old medical mystery and in the ... invasive fungal infections, which kill about 1.5 million people a ... action of amphotericin, an antifungal drug that has been in ... is nearly as toxic to human cells as it is ... of the new findings appears in Nature Chemical Biology ...
(Date:4/15/2014)... School of Medicine have identified a mechanism that explains ... disease and why the virus is able to persist ... hard-to-kill pathogen, which infects an estimated 200 million people ... mitochondria dismantling the cell,s innate ability to fight ... , The study, published in today,s issue of the ...
(Date:4/14/2014)... children orphaned by HIV/AIDS in South Africa may provide ... emotional behavior issues in other areas of the world, ... research that could lead to successful interventions. , ... the United Nations mentions that due to the HIV/AIDS ... Sub-Saharan African, children are at an increased risk for ...
(Date:4/14/2014)... Va., USA The International and American Associations ... titled "Rare Bone Diseases and Their Dental, Oral, ... Sunday O. Akintoye, Andrea B. Burke, Alison M. ... Gafni, Janice S. Lee, Mary Scott Ramnitz, Martha ... in the OnlineFirst portion of the IADR/AADR ...
Breaking Medicine News(10 mins):Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Breaking bad mitochondria 2Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Rare bone diseases and their dental, oral and craniofacial manifestations 2
... Practice Arm of the School,s Department of Forensic ... Jan. 30 The Chicago School of ... its psychology services to the legal sector and ... thanks to its new Forensic Center, which was ...
... Kroger Co. (NYSE: KR ),said today it is ... stores,because the product was associated with peanut butter supplied by ... Stores under the following names in ... Kroger, Ralphs, Fred Meyer, Food 4 Less, Fry,s,King Soopers, ...
... grid of small arteries at the surface of the brain ... supply to tissue starved of nutrients and oxygen following a ... is optimistic news," said David Kleinfeld, a physics professor at ... flow in animal models of stroke. , Damage from stroke ...
... ) AMDL, Inc. (NYSE Alternext US: ADL), a vertically ... the US, announced today the second and final closing ... notes and warrants. The exclusive placement agent for ... on December 8, 2008, AMDL sold $1,077,500 of 12% ...
... school shootings, other tragedies , , FRIDAY, Jan. 30 (HealthDay ... people into hotheads. , A University of Kentucky study ... likely to view other people,s actions as hostile and ... , The researchers said their findings may help explain ...
... up bad lipoproteins, researchers say , , FRIDAY, Jan. ... (HDL) -- the "good" cholesterol -- may hold ... the deadly cardiovascular disease it can cause. , ... is close in size to natural HDL with ...
Cached Medicine News:Health News:New Chicago School of Professional Psychology Forensic Center Opens Doors to the Community 2Health News:New Chicago School of Professional Psychology Forensic Center Opens Doors to the Community 3Health News:Kroger Recalls Nut Topping Due to Possible Health Risk 2Health News:Mesh-like network of arteries adjusts to restore blood flow to stroke-injured brain 2Health News:AMDL, Inc. Announces Final Closing of Private Placement of Senior Notes 2Health News:AMDL, Inc. Announces Final Closing of Private Placement of Senior Notes 3Health News:Those Who Feel Rejected Direct Hostility Toward Others 2Health News:Synthetic HDL Could Fight Heart Disease 2
... Detection Reagents provide molecular labs a more ... By using our MGB technology, combined with ... now able to provide molecular labs more ... of specific organisms or genetic mutations associated ...
... MGB Alert Detection Reagents provide molecular labs ... based assays. By using our MGB technology, ... Nanogen is now able to provide molecular ... acid sequences of specific organisms or genetic ...
... and most advanced fecal occult blood test ... immunochemical FOBT (iFOBT) with high specificity and ... detect bleeding associated with more cancers and ... its superior specificity for lower GI bleeding, ...
... Capture vital signs faster, easier, ... Signs LXi, the latest innovation in ... With Spot LXi, you get more ... the flexibility to customize it to ...
Medicine Products: